Abeona Therapeutics CEO sells 19,608 shares
The sale was tied to tax obligations from restricted stock vesting, and the chief executive officer directly held 1,286,500 shares afterward.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Abeona Therapeutics (ABEO) Chief Executive Officer Seshadri Vishwas sold 19,608 shares of common stock on September 29, 2026. The weighted average sale price was $5.1556 per share, with individual sale prices ranging from $5.1150 to $5.3000. The sale was to cover tax obligations associated with vesting restricted stock awards; Vishwas directly held 1,286,500 shares afterward. No Rule 10b5-1 plan is reported.
Insights
Analyzing...
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 19,608 | $5.1556 | $101K |
Footnotes (2)
- F1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1150 to $5.3000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Key Figures
Key Terms
weighted average price financial
restricted stock awards financial
tax obligations financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.